Circular RNA Hsa_Circ_0002483 Promotes Growth and Invasion of Lung Adenocarcinoma by Sponging miR-125a-3p

Jun Wan  
Shenzhen People's Hospital

Guanggui Ding  
Shenzhen People's Hospital

Min Zhou  
Shenzhen People's Hospital

Xiean Ling  
Shenzhen People's Hospital

ZhanPeng Rao (zhanpengrao@163.com)  
Shenzhen People's Hospital  https://orcid.org/0000-0002-3794-0149

Primary research

Keywords: hsa_circ_0002483, miR-125a-3p, growth, invasion, lung adenocarcinoma

DOI: https://doi.org/10.21203/rs.3.rs-742632/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: Increasing evidence indicates that the aberrant expression of circular RNAs (circRNAs) is involved in the pathogenesis and progression of lung adenocarcinoma (LUAC). However, the function and molecular mechanisms of hsa_circ_0002483 (circ_0002483) in LUAC remain unclear.

Methods: The association between circ_0002483 expression and clinicopathological characteristics and prognosis in patients with LUAC was analyzed by fluorescence in situ hybridization. The functional experiments such as MTT, colony formation and Transwell assays and a subcutaneous tumor model were conducted to determine the role of circ_0002483 in LUAC cells. The specific binding between circ_0002483 and miR-125a-3p was validated by RNA immunoprecipitation, luciferase gene report and qRT-PCR assays. The effects of circ_0002483 on miR-125a-3p-mediated C-C motif chemokine ligand 4 (CCL4)-CCR5 axis were assessed by Western blot analysis.

Results: We found that circ_0002483 was upregulated in LUAC tissue samples and associated with TNM stage and poor survival in patients with LUAC. Knockdown of circ_0002483 inhibited proliferation, colony formation and invasion of A549 and PC9 cells in vitro, whereas overexpression of circ_0002483 harbored the opposite effects. Furthermore, circ_0002483 sponged miR-125a-3p and negatively modulated its expression. CCL4 was identified as a direct target of miR-125a-3p. The rescue experiments showed that miR-125a-3p mimics reversed the tumor-promoting effects of circ_0002483 by targeting CCL4-CCR5 axis in A549 and PC9 cells. In addition, the in vivo experiment further validated that knockdown of circ_0002483 repressed tumor growth.

Conclusions: Our findings demonstrated that circ_0002483 could act as a sponge of miR-125a-3p to upregulate CCL4-CCR5 axis, contributing to the tumorigenesis of LUAC, and represent a potential therapeutic target for LUAC.

Introduction

Lung cancer is one of the most malignant tumors and its incidence and mortality are increasing rapidly, threatening to the public health and human life [1]. With the development of treatment methods, lung adenocarcinoma (LUAC) as a subclass of non-small cell lung cancer (NSCLC) has been well-treated, but the advanced cases still harbors a poor prognosis due to its distant metastasis [2]. Accumulating data display that the aberrant expression of noncoding RNAs is associated with the prognosis and progression of LUAC [3–5]. Therefore, identification of cancer-related noncoding RNAs may provide potential biomarkers for the early detection of LUAC.

Circular RNA (circRNA) as a subclass of noncoding RNAs is characterized by covalently closed loop structures and RNA stability owing to resistance to RNase R [6]. Increasing data demonstrate that circRNAs are aberrantly expressed and associated with the prognosis and progression of LUAC [7–9]. Meanwhile, circRNAs act as oncogenic or suppressive factors in LUAC by interacting with RNA-binding protein or sponging miRNAs. For example, circXPO1 facilitates LUAC progression by interacting with
IGF2BP1 [10] and circ_0001588 contributes to LUAC by sponging miR-524-3p/NACC1 signaling [11]. circ-CAMK2A, circ-ANXA7 and circ-AASDH promote LUAC metastasis by regulating miR-615-5p/fibronectin1, miR-331/LAD1 and miR-140-3p/E2F7 axis [12–14], while circ_0018414 and circ-MTO1 suppress LUAD proliferation by sponging miR-6807-3p and miR-17 [15, 16]. Until now, the functional of circ_0002483 in LUAD remains undocumented.

MicroRNAs (miRNAs) as another substyle of noncoding RNAs can target mRNAs by post-transcriptional levels and serve as promising biomarkers for early diagnosis and prognosis of LUAC [17]. Some studies show that miR-125a-3p and miR-125a-5p, downregulated in NSCLC, possess the inverse effects on migration and invasion of lung cancer cells [18], and downregulation of miR-125a-3p is associated with tumorigenesis and poor prognosis in patients with NSCLC [19]. Moreover, miR-125a-3p represses lung cancer growth and invasion by regulating the mouse double minute 2 homolog/p53 signaling [20], and NSCLC proliferation and migration by targeting metastasis-associated gene 1 [21]. miR-125a-3p is also sponged by IncRNA MALAT1 to regulate FOXM1 expression in hepatocellular carcinoma [22], and sponged by circ-MAPK4 in gliomas, circ_0012919 in systemic lupus erythematosus and circLMF1 in aortic smooth muscle cells [23–25].

In the present study, we identified a differentially-expressed hsa_circ_0002483 between LUAC and normal tissue samples, and found that upregulation of circ_0002483 was associated with TNM stage and poor survival in patients with LUAC. Further in vitro and in vivo experiments verified that circ_0002483 promoted the growth and invasion of LUAC cells by sponging miR-125a-3p and upregulating CCL4-CCR5 axis, thereby providing a novel target for LUAC.

Materials And Methods

Clinical Samples

The tissue microarray (No. XT17-002) including 80 pair-matched LUAC samples was purchased from Shanghai Outdo Biotechnology (Shanghai, China). The clinical data of patients with LUAC as well as the expression of miR-125a-3p, miR-134-5p, miR-301a-5p, miR-222-5p, miR-501-5p, CCL4 and CCR5 were downloaded from TCGA dataset (http://xena.ucsc.edu/). The patients did not receive any chemotherapy, and the protocols were approved by the Ethics Committee of The Shenzhen People's Hospital.

Bioinformatic analysis

The circRNA profiling was used to identify the differentially-expressed circRNAs between LUAC and normal tissues and downloaded from the Gene Expression Omnibus (GEO) dataset (https://www.gcbi.com.cn/gclib/html/index).

Fluorescence In Situ Hybridization (FISH)

The probe sequence for hsa_circ_0002483 (5'- GTATCTGTCATATTCTTTGATAG AAGAAAAAAACGTGTCCAGCCGCTAAGAGTGCTCAGGCAT-3') and Biotin-labeled probe sequences for
miR-125a-3p (5’-ACAGGTGAGGTTCTTGGGA GCCAAAAAAAACTGGACGCTAATAGCATAGACACTCTTTAGA-3’) were used to analyze the expression of hsa_circ_0002483 (green fluorescent signal) and miR-125a-3p (red fluorescent signal) in LUAC tissue samples. The detailed description of FISH analysis was executed as previously reported [26].

**Cell Culture and Transfection**

LUAC cell lines (A549 and PC9) used in these studies were provided by Cell bank of Shanghai Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM medium supplemented with 10% heat-inactivated FBS in a humidified atmosphere containing 5% CO2 at 37°C. Lentivirus mediated si-circ_0002483 (5’- AACAGAATATGACAGATACCTdTdT-3’), its negative control (si-NC), circ_0002483 overexpression plasmids, miR-125a-3p mimics and inhibitors were provided by GenePharma (Shanghai, China) and used for transfection into A549 and PC9 cells.

**Quantitative Real-Time (qRT-PCR)**

RNA was extracted from A549 and PC9 cell lines using Trizol reagent (Invitrogen). One Step SYBR® PrimeScript™ PLUS RT-PCR Kit (Beijing, China) was used to detect the expression of circ_0002483, CCL4 and CCR5 in A549 and PC9 cells. TaqMan® MicroRNA Reverse Transcription Kit and TaqMan Universal Master Mix II (Thermo Fisher Scientific, Runcorn, UK) were used to examine miR-125a-3p levels. U6 or β-actin was used as an internal control. The data were quantified using 2^(-ΔΔCT) equation in triplicate. The primer sequences used were shown in Table S1.

**Western Blot Analysis**

A549 and PC9 cell lines were harvested and protein was extracted using RIPA lysis. Primary antibodies against anti-CCL4 (ab25129, abcam), anti-CCR5 (ab65850, abcam) and anti-GAPDH (ab8245, abcam) were diluted (1:1000) and incubated overnight at 4°C. After rinsing, the polyvinylidene fluoride (PVDF) membrane of the antibodies was transferred onto the system. Captured signal was quantified by Image Lab Software 3.0 (Bio-Rad), and GAPDH was used as an internal parameter.

**MTT, Colony formation and Transwell Assays**

Cell viability, colony formation and invasive capabilities were conducted by MTT and Transwell assays according to the previous report [26].

**Actinomycin D and RNase R Treatment**

Transcription was prevented by the addition of 2 mg/ml Actinomycin D and DMSO (Sigma-Aldrich, St. Louis, MO, USA) was used as the control group. Total RNA was incubated for 30 min at 37°C with 3 U/μg of RNase R (Epicentre Technologies, Madison, WI, USA).

**Dual-Luciferase Reporter Assay**
A549 and PC9 cells were seeded into 24-well plates, and PRL-TK-Luc report vectors containing WT or Mut 3’UTR of circ_0002483 and CCL4 were co-transfected with miR-125a-3p mimic or inhibitor into A549 and PC9 cell lines. After the transfection for 48 h, luciferase activities were detected with a dual-luciferase reporter system (Promega, Madison, WI).

RNA Immunoprecipitation

RNA immunoprecipitation (RIP) assay was conducted using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA) according to the manufacturer's instructions.

Animal Experiments

Six-week-old female immune-deficient nude mice (BALB/c-nu) were injected subcutaneously with $5 \times 10^7$ A549 cells stably transfected with si-circ_0002483 or si-NC. Mice were monitored daily and developed a subcutaneous tumor. The tumor volume was detected every other day by using a formula: volume = length x width$^2$/2. This study was approved by Animal Ethics Committee of The Shenzhen People's Hospital.

Immunohistochemistry (IHC)

Ki-67 levels in xenograft tumor tissues were assessed using IHC assay. The detailed description of IHC was conducted as previously reported [4].

Statistical Analysis

Statistical analyses were performed by SPSS 20.0 (IBM, SPSS, Chicago, IL, USA) and GraphPad Prism. Student's t-test or Chi-square test was used to estimate the statistical significance for comparisons of two groups. Pearson correlation analysis was used to analyze the correlations. Overall survival curve was drawn with the Kaplan-Meier and log-rank test. $P < 0.05$ was considered statistical significance.

Results

Upregulation of circ_0002483 was associated with poor survival in patients with LUAC

The GEO dataset (GSE101684) was used to screen the differentially-expressed circRNAs between LUAC and non-cancerous tissue samples and top 10 upregulated or downregulated circRNAs were identified according to the FC > 2 and $P < 0.01$, of which hsa_circ_0002483 harbored a remarkable elevation in LUAC (Figure 1A). Then, FISH analysis validated that circ_0002483 expression levels were increased in pair-matched LUAC tissue samples as compared with the non-cancerous tissues (Figure 1B; $n = 80$, $P = 0.01$). The similar result was shown in LUAC patients with stage III-IV ($n = 42$) as compared with those with stage I-II ($n = 38$) (Figure 1C; $P = 0.02$).
In addition, we analyzed the association of circ_002483 with the clinicopathological characteristics in patients with LUAC and found that elevated expression of circ_002483 was related with TNM stage (Table 1; \(P = 0.048\)) rather than other parameters \((P > 0.05)\) in LUAC. On the basis of the cutoff value of circ_002483, we divided the cases into circ_002483-high \((n = 43)\) and circ_002483-low groups \((n = 37)\). Kaplan-Meier analysis uncovered that the patients with circ_002483-high group possessed a poorer survival as compared with those with circ_002483-low expression (Figure 1D; \(P = 0.014\)). Univariate and Multivariate analysis unveiled that TNM stage and pathological stage rather than circ_002483 expression are independent prognostic factors of poor survival in patients with LUAC (Tables S2).

**Identification of a novel circ_0002483 and its cellular localization**

It is indicated that hsa_circ_0002483 (chr8:141874410-141900868) is originated from exon 2, 6 regions within protein tyrosine kinase 2 (PTK2) locus, and the spliced sequence is about 482 bp (Figure 2A). The back-spliced junction of circ_0002483 was amplified by divergent primer and circ_0002483 could be amplified from only cDNA but not gDNA in A549 cells (Figure 2B). Relative to linear PTK2, circ_0002483 produced a resistance to RNase R treatment in A549 and PC9 cell lines, and circ_0002483 harbored a loop structure in LUAC cells (Figure 2C). After A549 cells were treated by Actinomycin D, qRT-PCR displayed that circ_0002483 was more stable than PTK2 (Figure 2D). qRT-PCR and FISH analysis revealed that circ_0002483 was mainly localized in the cytoplasm of LUAC cells and tissues (Figure 2E, F).

**Circ_0002483 facilitated proliferation, colony formation and invasion in vitro**

Upregulation of circ_0002483 in LUAC suggested that it might be an oncogenic factor. To test this hypothesis, we evaluated the function of circ_0002483 in A549 and PC9 cells and constructed the overexpression vectors and the siRNA against circ_0002483. As indicated in Figure 3A, the overexpression vectors and the siRNA of circ_0002483 could markedly increase and decrease the expression of circ_0002483 in A549 and PC9 cell lines, respectively. MTT assay was conducted to chart the growth curve which indicated that upregulation of circ_0002483 obviously increased the proliferation viability of A549 and PC9 cells, while downregulation of circ_0002483 repressed cell growth (Figure 3B). Colony formation assay further verified that the cell colony number of A549 and PC9 was remarkably elevated by upregulation of circ_0002483 and reduced by downregulation of circ_0002483 (Figure 3C, D). In addition, the effects of circ_0002483 on LUAC cell invasion were estimated by Transwell assay, which indicated that overexpression of circ_0002483 increased invasive capabilities of A549 and PC9 cells, while knockdown of circ_0002483 harbored the opposite effects (Figure 3E, F).

**Circ_0002483 was negatively associated with miR-125a-3p expression in LUAC tissue samples**

To demonstrate the underlying mechanisms of circ_0002483 in LUAC cells, we identified the binding sites of 5 miRNAs with circ_0002483 3’UTR by Circular RNA profiling and Interactome (Figure 4A). TCGA cohort showed that, relative to the other 4 miRNAs, only miR-125a-3p possessed a decreased expression in paired \((n = 39)\) and unpaired LUAC tissue samples \((n = 448, \text{Figure 4B})\). The downregulation and
cytoplasmic location of miR-125a-3p in pair-matched LUAC tissues were further confirmed by FISH analysis \((n = 80, P = 0.025; \text{Figure 4C-E})\). Pearson correlation analysis demonstrated that circ_0002483 harbored a negative correlation with miR-125a-3p expression in LUAC tissue samples \((P = 0.036; \text{Figure 4E})\).

Then, we analyzed the association of miR-125a-3p with clinicopathological characteristics in patients with LUAC (Table S3) and found that miR-125a-3p expression was related with gender \((P = 0.012)\) and lymph node metastasis \((P = 0.013)\) in patients with LUAC. However, the patients with miR-125a-3p-low expression showed no difference in poor survival and tumor recurrence as compared with those with miR-378a-3p-high expression (Figure S1).

**Circ_0002483 acted as a sponge of miR-125a-3p**

The specific binding sites of miR-125a-3p with WT or Mut circ_0002483 3'UTR were demonstrated in Figure 5A. To determine whether circ_0002483 could bind with miR-125a-3p, we co-transfected A549 and PC9 cells with WT or Mut circ_0002483 3'UTR reporter vectors and miR-125a-3p mimics or inhibitor, and found that miR-125a-3p mimics decreased the luciferase activities of WT circ_0002483 3'UTR in A549 and PC9 cells, while miR-125a-3p inhibitor enhanced such an effect (Figure 5B). But, miR-125a-3p exhibited no effects on those of Mut circ_0002483 3'UTR. Further qRT-PCR analysis indicated that upregulation of circ_0002483 reduced the expression of miR-125a-3p, and downregulation of circ_0002483 increased its expression (Figure 5C, D), whereas miR-125a-3p exhibited no effects on circ_0002483 expression in A549 and PC9 cells (Figure S2). Moreover, RIP assay was executed for Ago2 protein in A549 and PC9 cells, and the endogenous expression of circ_0002483 and miR-125a-3p pulled down from Ago2-expressed A549 and PC9 cells, indicated by qRT-PCR analysis was mainly enriched in Ago2 pellet relative to the input control (Figure 5E, F). After co-transfection with circ_0002483 and miR-125a-3p mimics or si-circ_0002483 and miR-125a-3p inhibitors into A549 and PC9 cells for 5 days, we found that miR-125a-3p suppressed the proliferation viability and attenuated circ_0002483-caused cell proliferation, while miR-125a-3p inhibitors displayed the opposite effects (Figure 5G).

**MiR-125a-3p reversed circ_0002483-caused upregulation of CCL4-CCR5 axis**

The targets of miR-125a-3p were identified by Targetscan7.1 and mirPathv.3 and the binding sites of miR-125a-3p with 3'UTR of CCL4 were demonstrated in Figure 6A. To determine whether miR-125a-3p could bind with 3'UTR of CCL4, we co-transfected A549 and PC9 cells with WT or Mut CCL4 3'UTR reporter vectors and miR-125a-3p mimics or inhibitor, and found that miR-125a-3p mimics decreased the luciferase activities of WT CCL4 3'UTR in A549 and PC9 cells, however, miR-125a-3p exhibited no effects on those of Mut CCL4 3'UTR (Figure 6B). TCGA cohort indicated that CCL4 and CCR5 were upregulated in 515 LUAC tissue samples (Figure 6C, D; \(P < 0.0001\)) and miR-125a-3p harbored a negative correlation with both of them in LUAC (Figure 6E; \(P < 0.05\)). In addition, we found that high expression of CCL4 harbored no association with clinicopathological features in patients with LUAC with (Table S4), and the patients with CCL4-high expression possessed no difference in poor survival and tumor recurrence relative to those with CCL4-low expression (Figure S3). Moreover, qRT-PCR and Western blot analyses demonstrated that
miR-125a-3p inhibited the expression of CCL4 and CCR5 and reversed circ_0002483-caused upregulation of CCL4-CCR5 axis in A549 cells (Figure 6F, G).

**Knockdown of circ_0002483 repressed cell growth in vivo**

To ascertain the effects of circ_0002483 on LUAC tumor growth *in vivo*, stably transfected A549 cells infected with si-NC or si-circ_0002484 were constructed and subcutaneously injected into 6-week old female nude mice (Figure 7A). Moreover, the tumor volume and weight in the si-circ_0002484 group were smaller and lighter than the si-NC group (Figure 7B, C). Hematoxylin and eosin (HE) staining and IHC of Ki-67 indicated that knockdown of circ_0002483 inhibited cell proliferation as compared with the si-NC group (Figure 7D).

**Discussion**

A sea of studies have shown that the aberrant expression of circRNA is related with the prognosis, pathogenesis and progression in multiple cancers including LUAC [26–28]. hsa_circ_0000792 and circ_0013958 are identified as potential biomarkers of LUAD [7, 9] and hsa_circ_0000190 is linked to tumor progression and poor prognosis in advanced lung cancer [8]. The tissue and plasmid levels of hsa_circ_0003221 (circPTK2) are correlated with poor differentiation and lymph node metastasis in bladder cancer [29]. Herein, we identified a novel differentially-expressed hsa_circ_0002483 (circPTK2) in LUAD tissue samples and found that, elevated expression of circ_0002483 was associated with TNM stage and poor survival in patients with LUAD and might provide a potential prognostic factor for LUAD.

Previous studies indicated that circRNAs have double-effects in LUAD progression. For example, circCSNK1G3 and circ-SOX4 facilitate growth and metastasis of LUAC by sponging miR-143-3p and miR-1270 [30, 31], whereas circCRIM1 and circ-000881 repress LUAC by sponging miR-182 and miR-665 [32, 33]. Moreover, circ_0008305 (circPTK2) is shown to inhibit the metastasis of NSCLC [34]. Herein, we found a novel circ_0002483 (circPTK2) and confirmed that knockdown of circ_0002483 suppressed growth and invasion of LUAD cells, while ectopic expression of circ_0002483 exhibited the tumor-promoting effects. Our results indicated that circ_0002483 might be an oncogenic factor in LUAC.

Increasing studies have indicated that circRNAs act as miRNA sponges to regulate LUAD progression [30–33]. Herein, we found that circ_0002483 could bind with Ago2-miR-125a-3p complex and negatively regulate miR-125a-3p expression in LUAC cells. Previous studies showed that miR-125a-3p can be also sponged by circ-MAPK4 and circARFGEF1 to regulate cell proliferation and invasion in glioma and LUAC [23, 35]. These studies suggested that, circ_0002483 might act as a sponge of miR-125a-3p to promote LUAC progression.

It has been shown that miR-125a-3p is downregulated and inhibits cell growth and invasion of LUAC [18–21]. In accordance, we found that miR-125a-3p expression was decreased in LUAC and associated with lymph node metastasis in patients with LUAC. miR-125a-3p harbored a negative correlation with circ_0002483 expression, repressed cell proliferation and reversed circ_0002483-induced tumor-
promoting effects. In addition, CCL4-CCR5 axis contributes to breast cancer metastasis [36] and targeting CCR5 inhibits colorectal cancer liver metastasis [37]. We herein identified that CCL4 was upregulated in LUAC tissues and regarded as a direct target of miR-125a-3p. miR-125a-3p downregulated CCL4-CCR5 axis and reversed circ_0002483-caused upregulation of this axis. Our results suggested that circ_0002483 might act as a sponge of miR-125a-3p to upregulate CCL4-CCR5 axis, contributing to the tumorigenesis of LUAC.

Taken together, elevated expression of circ_0002483 is associated with TNM stage and poor survival in patients with LUAC. circ_0002483 facilitates the tumorigenesis and invasion of LUAC by sponging miR-125a-3p and upregulating CCL4-CCR5 axis. Our findings might offer a potential therapeutic biomarker for LUAC.

Declarations

Acknowledgements

None.

Authors’ contributions

JW and ZR designed the experiments. JW, GD and ZR performed the experiments. GD and MZ analyzed the data. JW, GD and XL wrote the manuscript. All authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the research to ensure that the accuracy or integrity of any part of the work is appropriately investigated and resolved.

Funding

This work was supported by Basic Research Project of Shenzhen Science and Technology Program (Natural Science Foundation; No. JCYJ20190807144201675).

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors have declared that no competing interest exists.

Ethics approval and consent to participate

The use of LUAC tissue samples was approval from the Ethical Review Board of The Shenzhen People's Hospital (Shenzhen, China).

Consent for publication
References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
2. Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7:170070.
3. Naeli P, Yousefi F, Ghasemi Y, Savardashtaki A, Mirzaei H. The Role of MicroRNAs in Lung Cancer: Implications for Diagnosis and Therapy. Curr Mol Med. 2020;20:90-101.
4. Cui D, Feng Y, Shi K, Zhang H, Qian R. Long non-coding RNA TRPM2-AS sponges microRNA-138-5p to activate epidermal growth factor receptor and PI3K/AKT signaling in non-small cell lung cancer. Ann Transl Med. 2020;8:1313.
5. Han X, Jiang H, Qi J, Li J, Yang J, et al. Novel IncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma. Cell Death Dis. 2020;11:999.
6. Qu S, Zhong Y, Shang R, Zhang X, Song W, et al. The emerging landscape of circular RNA in life processes. RNA Biol. 2017;14:992-999.
7. Li S, Sun X, Miao S, Lu T, Wang Y, et al. hsa_circ_0000729, a potential prognostic biomarker in lung adenocarcinoma. Thorac Cancer. 2018;9:924-930.
8. Luo YH, Yang YP, Chien CS, Yarmishyn AA, Ishola AA, et al. Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers. Cancers (Basel). 2020;12:1740.
9. Zhu X, Wang X, Wei S, Chen Y, Chen Y, et al. hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma. FEBS J.;284:2170-2182.
10. Huang Q, Guo H, Wang S, Ma Y, Chen H, et al. A novel circular RNA, circXPO1, promotes lung adenocarcinoma progression by interacting with IGF2BP1. Cell Death Dis. 2020;11:1031.
11. Sun Z. Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling. Life Sci. 2020;259:118157.
12. Du J, Zhang G, Qiu H, Yu H, Yuan W. The novel circular RNA circ-CAMK2A enhances lung adenocarcinoma metastasis by regulating the miR-615-5p/fibronectin 1 pathway. Cell Mol Biol Lett. 2019;24:72.
13. Wang Y. circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis. Cancer Cell Int. 2021;21:85.
14. Wang Y, Wo Y, Lu T, Sun X, Liu A, et al. Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression. Transl Lung Cancer Res. 2021;10:57-70.
15. Yao Y, Zhou Y, Hua Q. circRNA hsa_circ_0018414 inhibits the progression of LUAD by sponging miR-6807-3p and upregulating DKK1. Mol Ther Nucleic Acids. 2021;23:783-796.
16. Zhang B, Chen M, Jiang N, Shi K, Qian R. A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma. Cancer Biol Ther. 2019;20:1127-1135.

17. Inamura K, Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med. 2016;5:36.

18. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 2010;10:318.

19. Hou L, Luo P, Ma Y, Jia C, Yu F, et al. MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017;14:4441-4448.

20. Li S, Li X, Zhao H, Gao M, Wang F, et al. Overexpression of microRNA-125a-3p effectively inhibits the cell growth and invasion of lung cancer cells by regulating the mouse double minute 2 homolog/p53 signaling pathway. Mol Med Rep. 2015;12:5482-6.

21. Zhang H, Zhu X, Li N, Li D, Sha Z, et al. miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 2015;47:496-503.

22. Liu S, Qiu J, He G, Liang Y, Wang L, et al. LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression. J Cancer. 2019;10:6649-6659.

23. He J, Huang Z, He M, Liao J, Zhang Q, et al. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas. Mol Cancer. 2020;19:17.

24. Zhang C, Wang X, Chen Y, Wu Z, Zhang C, et al. The down-regulation of hsa_circ_0012919, the sponge for miR-125a-3p, contributes to DNA methylation of CD11a and CD70 in CD4+ T cells of systemic lupus erythematos. Clin Sci (Lond). 2018;132:2285-2298.

25. Yang Y, Mao W, Wang L, Lu L, Pang Y. Circular RNA circLMF1 regulates PDGF-BB-induced proliferation and migration of human aortic smooth muscle cells by regulating the miR-125a-3p/VEGFA or FGF1 axis. Clin Hemorheol Microcirc. 2021. doi: 10.3233/CH-211166.

26. Zhang J, Liu H, Hou L, Wang G, Zhang R, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017;16:151.

27. Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020;19:110.

28. Zhou J, Zhang S, Chen Z, He Z, Xu Y, et al. CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1. Cell Death Dis. 2019;10:885.

29. Xu ZQ, Yang MG, Liu HJ, Su CQ. Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. J Cell Biochem. 2018;119:3317-3325.

30. Lu T, Qiu T, Han B, Wang Y, Sun X, et al. Circular RNA circCSNK1G3 induces HOXA10 signaling and promotes the growth and metastasis of lung adenocarcinoma cells through hsa-miR-143-3p.
31. Gao N, Ye B. Circ-SOX4 drives the tumorigenesis and development of lung adenocarcinoma via sponging miR-1270 and modulating PLAGL2 to activate WNT signaling pathway. Cancer Cell Int. 2020;20:2.

32. Wang L, Liang Y, Mao Q, Xia W, Chen B, et al. Circular RNA circCRIM1 inhibits invasion and metastasis in lung adenocarcinoma through the microRNA (miR)-182/miR-93-leukemia inhibitory factor receptor pathway. Cancer Sci. 2019;110:2960-2972.

33. Huang C, Yue W, Li L, Li S, Gao C, et al. Circular RNA hsa-circ-000881 suppresses the progression of lung adenocarcinoma in vitro via a miR-665/PRICKLE2 axis. Ann Transl Med. 2021;9:498.

34. Wang L, Tong X, Zhou Z, Wang S, Lei Z, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer. Mol Cancer. 2018;17:140.

35. Yao S, Jia X, Wang F, Sheng L, Song P, et al. CircRNA ARFGEF1 functions as a ceRNA to promote oncogenic KSHV-encoded viral interferon regulatory factor induction of cell invasion and angiogenesis by upregulating glutaredoxin 3. PLoS Pathog. 2021;17:e1009294.

36. Sasaki S, Baba T, Nishimura T, Hayakawa Y, Hashimoto S, et al. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis. Cancer Lett. 2016;378:23-32.

37. Pervaiz A, Zepp M, Georges R, Bergmann F, Mahmood S, et al. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis. J Cancer Res Clin Oncol. 2021;147:73-91.

Tables

Table 1. The association of circ_0002483 expression with clinicopathological characteristics in patients with LUAC
| Variables                          | Cases (n) | circ_0002483 |   |   |   |
|-----------------------------------|-----------|--------------|---|---|---|
|                                   |           | High         | Low |   | P value |
| **Total**                         | 80        | 43           | 37 |   |   |
| **Age (years)**                   |           |              |    |   |   |
| ≥60                               | 40        | 24           | 16 |   | 0.265 |
| <60                               | 40        | 19           | 21 |   |   |
| **Sex**                           |           |              |    |   |   |
| Male                              | 41        | 22           | 19 |   | 0.987 |
| Female                            | 39        | 21           | 18 |   |   |
| **Pathologic stage**              |           |              |    |   |   |
| I-II                              | 41        | 24           | 17 |   | 0.382 |
| III-IV                            | 39        | 19           | 20 |   |   |
| **Tumor size (cm)**               |           |              |    |   |   |
| ≥3                                | 57        | 33           | 24 |   | 0.245 |
| <3                                | 23        | 10           | 13 |   |   |
| **TNM staging**                   |           |              |    |   |   |
| I-II                              | 38        | 16           | 22 |   | 0.048 |
| III-IV                            | 42        | 27           | 15 |   |   |
| **Lymph node metastasis**         | 1         |              |    |   |   |
| Negative                          | 41        | 21           | 20 |   | 0.644 |
| Positive                          | 39        | 22           | 17 |   |   |

**Figures**
Figure 1

Upregulation of circ_0002483 was associated with poor survival in patients with LUAC. (A) Hierarchical clustering of differentially expressed circRNAs between LUAC and normal tissue samples. (B) FISH analysis of the expression levels of circ_0002483 in 80 pair-matched LUAC tissue samples. (C) FISH analysis of the expression levels of circ_0002483 in LUAC with stage I+II and stage III+IV. (D) Kaplan-Meier analysis of the association of circ_0002483 expression with overall survival in patients with LUAC.
Figure 2

Identification of a novel circ_0002483 in LUAC cells. (A) The genomic loci of circ_0002483. (B) PCR product of circ_0002483 in agarose gel electrophoresis and convergent and divergent primers for confirmation of the closed loop structure. (C) qRT-PCR analysis of circ_0002483 and PTK2 expression levels after treatment with RNase R in A549 and PC9 cells. (D) qRT-PCR analysis of the stability of circ_0002483 and PTK2 after treatment with Actinomycin D in A549 cells. (E, F) qRT-PCR and FISH
analysis of the location of circ_0002483 in LUAC cells and tissues. Data shown are the mean ± SEM of three experiments. ***P < 0.001.

Figure 3

Circ_0002483 promoted proliferation, colony formation and invasion in vitro. (A) qRT-PCR analysis of the expression levels of circ_0002483 after the transfection with circ_0002483 overexpression vectors or si-circ_0002483 in A549 and PC9 cells. (B) MTT analysis of the cell proliferation viability after transfection with circ_0002483 overexpression vectors or si-circ_0002483 in A549 and PC9 cells. (C, D) Colony formation analysis of cell colony number after transfection with circ_0002483 overexpression vectors or si-circ_0002483 in A549 and PC9 cells. (E, F) Transwell analysis of cell invasion capabilities after transfection with circ_0002483 overexpression vectors or si-circ_0002483 in A549 and PC9 cells. Data shown are the mean ± SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 4
Circ_0002483 harbored a negative correlation with miR-125a-3p expression in LUAC tissue samples. (A) The binding sites between circ_0002483 and multiple miRNAs. (B) TCGA analysis of the expression levels of 5 miRNAs in paired and unpaired LUAC tissue samples. (C-E) FISH analysis of the expression levels and cellular location of miR-125a-3p, and Pearson correlation analysis of the correlation of circ_0002483 with miR-125a-3p expression in LUAC tissue samples (n = 80).

Figure 5

Circ_0002483 acted as a sponge of miR-125a-3p in LUAC cells. (A) Schematic representation of the binding sites of miR-125a-3p with WT or Mut circ_0002483 3’UTR. (B) Estimation of luciferase activities of WT or Mut circ_0002483 3’UTR after co-treatment with miR-125a-3p mimics or inhibitor and WT or Mut circ_0002483 3’UTR reporter vectors in A549 and PC9 cells. (C) qRT-PCR analysis of the expression levels of miR-125a-3p after transfection with its mimics and inhibitor in A549 and PC9 cells. (D) qRT-PCR analysis of the expression levels of miR-125a-3p after transfection with circ_0002483 overexpression vectors or si-circ_0002483 in A549 and PC9 cells. (E, F) RIP analysis of the enrichment levels of
circ_0002483 and miR-125a-3p pulled down from Ago2 protein in A549 and PC9 cells. (G) MTT analysis of cell proliferation viability after co-transfection with circ_0002483 overexpression vectors and miR-378a-3p mimics in A549 cells or si-circ_0002483 and miR-125a-3p inhibitor in PC9 cells. Data shown are the mean ± SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 6

miR-125a-3p reversed circ_0002483-caused upregulation of CCL4-CCR5 axis. (A) Schematic representation of the binding sites of miR-125a-3p with WT or Mut CCL4 3’UTR. (B) Estimation of luciferase activities of WT or Mut CCL4 3’UTR after co-treatment with miR-125a-3p mimics and WT or Mut CCL4 3’UTR reporter vectors in A549 and PC9 cells. (C, D) TCGA analysis of the expression levels of CCL4 and CCR5 in LUAC tissue samples (n = 515). (E) Pearson correlation analysis of the correlation of miR-125a-3p with CCL4 and CCR5 expression in LUAC tissue samples. (F, G) qRT-PCR and Western blot analysis of the expression levels of CCL4 and CCR5 after co-transfection with circ_0002483
overexpression vectors and miR-125a-3p mimics in A549 cells. Data shown are the mean ± SEM of three experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

**Figure 7**

Knockdown of circ_0002483 repressed LUAC tumor growth. (A) Representative photographs of the subcutaneous xenograft tumors and assessment of the tumor growth curve after treatment with si-circ_0002483 or si-NC transfected A549 cells. (B, C) Comparison of tumor volume and weight between si-circ_0002483 and si-NC groups. (D) HE and IHC analysis of the Ki-67 expression levels between si-circ_0002483 and si-NC groups.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigureS1.pdf
- FigureS2.pdf
- FigureS3.pdf
- Supplementarydata.docx